HP-518 is under clinical development by Hinova Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase I drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HP-518’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HP-518 overview

HP-518 is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and triple negative breast cancer (TNBC). It is administered through oral route in form of tablet. The drug candidate is a PROTAC (proteolysis targeting chimera) acts by targeting androgen receptor (AR) and CRBN. It is being developed based on protein degradation drug discovery platform.

Hinova Pharmaceuticals overview

Hinova Pharmaceuticals (Hinova Pharma) operates as a drug discovery and development company. The Company focuses on the therapeutic areas where there are unmet medical needs. Hinova Pharmaceuticals serves customers globally. Hinova Pharma is headquartered in Chengdu, Sichuan, China.

For a complete picture of HP-518’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.